MedTrace Logo

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

NCT00492778 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2023-03-29

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with endometrial cancer that has come back. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving radiation therapy together with cisplatin is more effective than radiation therapy alone in treating patients with endometrial cancer.

Conditions

  • Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
  • Endometrial Mucinous Adenocarcinoma
  • Endometrial Squamous Cell Carcinoma
  • Recurrent Endometrial Clear Cell Adenocarcinoma
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Endometrial Serous Adenocarcinoma
  • Recurrent Endometrial Undifferentiated Carcinoma
  • Recurrent Uterine Corpus Cancer

Interventions

RADIATION

3-Dimensional Conformal Radiation Therapy

Undergo 3-dimensional conformal radiation therapy

DRUG

Cisplatin

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

RADIATION

Internal Radiation Therapy

Given intracavitarily or interstitially

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • GOG Foundation

    lead NETWORK

Principal Investigators

  • Jonathan M Feddock · NRG Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-25
Primary Completion
2021-12-15

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00492778 on ClinicalTrials.gov